Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignancies

被引：0
|
作者：
Groves, Morris [2 ]
Hansen, Aaron [3 ]
Harb, Wael [4 ]
Curtis, Kelly [5 ]
Koga-Yamakawa, Erina [6 ]
Origuchi, Makoto [7 ]
Li, Zhonggai [7 ]
Iglesias, Jose [7 ]
Shaib, Walid [8 ]
Spira, Alexander [1 ]
机构：
[1] Virginia Canc Specialists, Fairfax, VA USA
[2] Texas Oncol Austin Midtown, Austin, TX USA
[3] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Horizon Oncol Res LLC, Lafayette, IN USA
[5] Syneos Hlth, Phoenix, AZ USA
[6] Sumitomo Dainippon Pharma Co Ltd, Cambridge, MA USA
[7] Boston Biomed Inc, Cambridge, MA USA
[8] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P355
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Talpaz, Moshe
    Erickson-Viitanen, Susan
    Hou, Kevin
    Hamburg, Solomon
    Baer, Maria R.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [42] Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
    Zucali, Paolo Andrea
    Lin, Chia-Chi
    Carthon, Bradley C.
    Bauer, Todd M.
    Tucci, Marcello
    Italiano, Antoine
    Iacovelli, Roberto
    Su, Wu-Chou
    Massard, Christophe
    Saleh, Mansoor
    Daniele, Gennaro
    Greystoke, Alastair
    Gutierrez, Martin
    Pant, Shubham
    Shen, Ying-Chun
    Perrino, Matteo
    Meng, Robin
    Abbadessa, Giovanni
    Lee, Helen
    Dong, Yingwen
    Chiron, Marielle
    Wang, Rui
    Loumagne, Laure
    Lepine, Lucie
    de Bono, Johann
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [43] Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study
    Harder, Signe
    Groenvold, Mogens
    Isaksen, Jesper
    Sigaard, Jarl
    Frandsen, Karin Bruun
    Neergaard, Mette Asbjoern
    Mondrup, Lise
    Herrstedt, Jorn
    SUPPORTIVE CARE IN CANCER, 2019, 27 (08) : 2849 - 2856
  • [44] Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study
    Signe Harder
    Mogens Groenvold
    Jesper Isaksen
    Jarl Sigaard
    Karin Bruun Frandsen
    Mette Asbjoern Neergaard
    Lise Mondrup
    Jørn Herrstedt
    Supportive Care in Cancer, 2019, 27 : 2849 - 2856
  • [45] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Fujita, Tomoko
    Sugibayashi, Ko
    Murayama, Kosho
    Yamamoto, Noboru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1795 - 1804
  • [46] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Nobuaki Matsubara
    Shota Kusuhara
    Noboru Yamamoto
    Kazuki Sudo
    Masahiko Yanagita
    Kosho Murayama
    Hisashi Kawasumi
    Deanna L. Russell
    Da Yin
    Toshio Shimizu
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 341 - 352
  • [47] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Shunsuke Kondo
    Satoru Iwasa
    Takafumi Koyama
    Tomoko Fujita
    Ko Sugibayashi
    Kosho Murayama
    Noboru Yamamoto
    International Journal of Clinical Oncology, 2022, 27 : 1795 - 1804
  • [48] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Matsubara, Nobuaki
    Kusuhara, Shota
    Yamamoto, Noboru
    Sudo, Kazuki
    Yanagita, Masahiko
    Murayama, Kosho
    Kawasumi, Hisashi
    Russell, Deanna L.
    Yin, Da
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (04) : 341 - 352
  • [49] Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study
    Naoki, Katsuhiko
    Igawa, Satoshi
    Uojima, Haruki
    Tsumura, Hideyasu
    Sengoku, Norihiko
    Karayama, Masato
    Shimomura, Akihiko
    Ohtake, Tohru
    Shio, Yutaka
    Hosokawa, Ayumu
    Komatsu, Yoshito
    Kumagai, Yuji
    CANCER, 2024, 130 (21) : 3745 - 3756
  • [50] An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK plus non-lung solid tumors and hematological malignancies (ASCEND-10).
    Moreno, Victor
    Kim, Tae Min
    Rha, Sun Young
    Longo, Federico
    Sathornsumetee, Sith
    Zhang, Shirong
    Hirschberg, Yulia
    Pramanik, Barnali
    Wamil, Barbara D.
    Kiss, Igor
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345